Submission of Newspaper Clippings regarding Audited Financial Results for the quarter and Year ended 31.03.2025 published on 01.06.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare Ltd (formerly Roxy Exports Limited, BSE scrip: 539561/REMLIFE) has submitted newspaper clippings of its audited Q4 and full-year FY25 results, which were published on 01.06.2025 in Financial Express (English) and Mumbai Lakshadeep (Marathi), as required under SEBI LODR Regulations 33 and 47. For the standalone business, full-year FY25 revenue from operations fell sharply to Rs 23,330.02 lakhs from Rs 40,627.78 lakhs in FY24, a drop of around 43% YoY. Q4 FY25 revenue stood at Rs 8,222.85 lakhs versus Rs 14,138.64 lakhs in Q4 FY24. The company reported a standalone net profit of Rs 153.20 lakhs for FY25 versus Rs 3,273.02 lakhs in FY24, a steep decline. On a quarterly basis, the net loss narrowed to Rs 264.34 lakhs in Q4 FY25 from a loss of Rs 5,372.04 lakhs in Q4 FY24. The consolidated FY25 net profit came in at Rs 212.94 lakhs with total income of Rs 41,605.37 lakhs.
Filing is a routine regulatory disclosure of results already published, so no new market-moving information. However, the sharp YoY revenue decline and significant drop in full-year profits are negatives that investors should weigh, even as the Q4 sequential loss narrowed materially.